Compare TG Therapeutics Inc (TGTX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? TG Therapeutics Inc trades at $54.83 (market cap $8.16B), while Wheaton Precious Metals Corp trades at $138.53 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 7.5× TG Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Wheaton Precious Metals Corp for 66 Days on average.
| TGTX | WPM | |
|---|---|---|
Market Cap | $8.16B | $61.17B |
Volume | 1,735,121 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $165.72 |
52-Week Low | $26.94 | $94.37 |
Typical Hold Time | 16 Days | 66 Days |
Enterprise Value | $8.37B | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Wheaton Precious Metals (WPM) trades at $138.1, up 3.3% today, with a bearish technical signal despite recent earnings beats. The company reported record 2025 revenue of $2.31B and net income of $1.47B, supported by strong margins. Analyst consensus is bullish with an 80% buy rating and a $164.80 price target, while news highlights growth ambitions targeting 1.2M ounces by 2030.
WPM offers exposure to gold and silver streaming with robust profitability, but faces risks from gold price volatility and high valuations. The stock's upside hinges on execution of its funded growth pipeline, though technical indicators suggest near-term resistance near $138.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
